查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733168

全球子宫颈发育不良市场规模（按诊断、最终用户、地区、范围和预测）

Global Cervical Dysplasia Market Size By Diagnostic (Diagnostic Tests, Diagnostic Devices), By End-User (Hospitals, Diagnostic Centers), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

子宫颈发育不良市场规模及预测

2024 年子宫颈发育不良市场规模价值 5.2268 亿美元，预计到 2032 年将达到 8.5506 亿美元，2026 年至 2032 年的复合年增长率为 7%。

消费者对子宫颈癌认识的提高促进了子宫颈发育不良市场的成长。此外，政府在疫苗接种、社会动员、筛检和社区教育方面的倡议，以及 HPV 感染的增加，导致子宫颈发育不良的诊断率增加。本研究报告对子宫颈发育不良市场进行了全面评估。它对细分市场、市场相关趋势、市场驱动因素、限制因素、机会、竞争格局等进行了详细的分析。

全球子宫颈发育不良市场定义

子宫颈发育不良是一种癌前病变，以子宫颈细胞异常生长为特征。子宫颈发育不良也称为子宫颈上皮内瘤。透过治疗和定期检查，您可以在癌症发展之前进行预防。子宫颈发育不良可发生在任何年龄，但最常见于 25 至 35 岁的女性。子宫颈发育不良是一种由人类乳突病毒 (HPV) 感染引发的性行为感染传染病。没有任何病征，疾病为无综合症。

根据感染细胞的类型，子宫颈发育不良分为腺泡细胞病变和上皮内病变两种。此疾病可以透过子宫颈抹片检查、HPV检测和阴道镜检查来诊断。子宫颈发育不良是一种可以透过破坏和切除异常区域来治疗的疾病。三种标准治疗方法分别是手术、放射线治疗、化疗、药物疗法、消融疗法和切除术（切除异常区域）。治疗方法方法多种多样，所需的手术方法根据癌症的进展和恶性程度而有所不同。

VMR 内部

产业报告中有哪些内容？

我们的报告包含可操作的数据和前瞻性的分析，可协助您制定宣传方案、建立商业计划、组织简报或撰写提案。

全球子宫颈发育不良市场概况

子宫颈发育不良是癌症诊断和治疗领域成长最快的细分市场之一。子宫颈癌处于癌前阶段，如果及早发现，可以有效治癒。消费者对此的认识不断提高，导致预测期内对子宫颈筛检测试的需求增加。此外，各已开发国家的政府机构正在实施筛检计划，以降低死亡率，改善公民的生活品质。此外，政府协会关于早期发现包括子宫颈发育不良在内的慢性疾病的建议是预测期内推动整个子宫颈发育不良市场发展的主要因素之一。

也存在一些限制市场成长的限制和障碍。等候核准、由于监管合规耗时而导致的药物不可用以及子宫颈发育不良市场研发所需的高成本等因素都是阻碍全球子宫颈发育不良市场整体成长的潜在限制因素。然而，技术的不断发展和新兴市场的尚未开发的潜力提供了有利可图的成长机会。

目录

第 1 章全球子宫颈发育不良市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球子宫颈发育不良市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球子宫颈发育不良市场（依诊断）

  • 概述
  • 诊断测试
    • HPV检测
    • 子宫颈抹片抹片检查
    • 切片检查检查
  • 诊断设备
    • 阴道镜检查

6. 全球子宫颈发育不良市场（依最终用户）

  • 概述
  • 医院
  • 诊断中心
  • 门诊手术中心
  • 其他的

7. 全球子宫颈发育不良市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东

8. 全球子宫颈发育不良市场的竞争格局

  • 概述
  • 各公司市场排名
  • 主要发展策略

第九章 公司简介

  • QIAGEN
  • F. Hoffmann La-Roche Ltd.
  • Quest Diagnostics
  • Becton, Dickinson and company
  • Abbott Healthcare Pvt. Ltd
  • OncoHealth Corporation, Inc.
  • Hologic, Inc.

第十章 附录

  • 相关调查
简介目录
Product Code: 32784

Cervical Dysplasia Market Size And Forecast

Cervical Dysplasia Market size was valued at USD 522.68 Million in 2024 and is projected to reach USD 855.06 Million by 2032, growing at a CAGR of 7% from 2026 to 2032

Growing consumer awareness regarding cervical cancer has led to risen growth of the Cervical Dysplasia Market. Furthermore, the government initiatives on vaccination, social mobilization, screening, and community education, and the increasing occurrence of HPV infection have also led to an expansion in the diagnosis of Cervical Dysplasia. The Global Cervical Dysplasia Market report provides a holistic evaluation of the market. The report provides an indepth analysis on the segments, market related trends, market drivers, restraints, opportunities along with the competitive landscape.

Global Cervical Dysplasia Market Definition

Cervical Dysplasia is a precancerous condition identified by abnormal growth of cells on the cervix. Cervical Dysplasia is also recognized as cervical intraepithelial neoplasia. It can be rectified before it becomes cancerous, by treatment and regular diagnosis. It usually strikes women of any age but more frequently between 25 to 35 years of age in women. Cervical Dysplasia is a sexually communicated disease-induced due to Human papillomavirus (HPV) infection. It does not show any symptoms, they are asymptomatic.

Cervical Dysplasia is classified in two varieties based on the type of cells it affects, involves glandular cell lesions and intraepithelial lesions. This condition can be diagnosed by a Pap test, HPV test, and colposcopy. Cervical Dysplasia is a condition that can be treated by the destruction and removal of the abnormal area. TSurgery, radiation therapy, chemotherapy, or medication combinations, ablation therapy, and resection (expulsion of the aberrant region) are the three types of standard treatment. There are various sorts of treatment alternatives, and the kind of surgical technique required relies on the stage and grade of cancer growth.

What's inside a VMR

industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cervical Dysplasia Market Overview

Cervical Dysplasia makes for one of the fastest-growing market segments in the area of cancer diagnosis and treatment. Cervical cancer is a precancerous stage and it can be effectively cured by early detection. Growing consumer awareness in this regard has headed to improved demand for cervical screenings in the forecast period. Moreover, government organizations in various developed countries administer screening programs in order to enhance the quality of life of the population by reducing the mortality rate. Furthermore, recommendations from government associations for early detection of chronic diseases including Cervical Dysplasia is one of the primary factors that is driving the overall Cervical Dysplasia Market over the forecast period.

There are certain constraints and barriers experienced that will limit the market growth. The factors such as pending approvals, unavailability of a therapeutic drug due to time-consuming regulatory compliance, and the high cost required for research and development in the market for Cervical Dysplasia are the potential restraints hampering the overall growth of the global Cervical Dysplasia Market. Nevertheless, the continuous developments in technologies, and untapped potential in emerging markets offer favorable growth opportunities.

Global Cervical Dysplasia Market: Segmentation Analysis

The Global Cervical Dysplasia Market is Segmented on the basis of Diagnostic, End-User, And Geography.

Cervical Dysplasia Market, By Diagnostic

  • Diagnostic Tests
  • Diagnostic Devices

Based on Diagnostic, the market is bifurcated into Diagnostic Tests, Diagnostic Devices. The diagnostic tests segment holds the largest market share during the forecast period. The factors that can be attributed to its efficacy, flexibility, reimbursement policies, and cost-effectiveness are accelerating the demand for this segment.

Cervical Dysplasia Market, By End-User

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

Based on End-User, the market is bifurcated into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, and Others. The hospital segment accounts for the largest market share through the forecast years. The factors that can be attributed to the availability of technologically advanced diagnostic devices and tests and the presence of various reimbursement policies enhance the demand for this segment.

Cervical Dysplasia Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the global Cervical Dysplasia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America holds the largest market share. The technological advancements, increase in prevalence of various associated diseases, rising awareness and screening programs, and ongoing projects will boost the market in the North American region.

Key Players

The "Global Cervical Dysplasia Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as QIAGEN, F. Hoffmann La-Roche Ltd., Quest Diagnostics, Becton, Dickinson and company, Abbott Healthcare Pvt. Ltd, OncoHealth Corporation, Inc., and Hologic, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally are also included in the competitive landscape section.

Key Developments

  • Both ASKA Pharmaceutical and KinoPharma, both Japanese pharmaceutical giants, agreed to a partnership agreement in January 2020 for the development and commercialization of medication candidates for cervical dysplasia in the market, which is now in the preclinical phase at KinoPharma. As part of the arrangement, ASKA will acquire exclusive rights to distribute the drug in Japan and will assist in the co-development of prospective therapeutic candidates in the future, while KinoPharma will earn upfront payments for the exclusive licencing.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CERVICAL DYSPLASIA MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL CERVICAL DYSPLASIA MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL CERVICAL DYSPLASIA MARKET, BY DIAGNOSTIC

  • 5.1 Overview
  • 5.2 Diagnostic Tests
    • 5.2.1 HPV Test
    • 5.2.2 Pap Smear Test
    • 5.2.3 Biopsy Test
  • 5.3 Diagnostic Devices
    • 5.3.1 Colposcope

6 GLOBAL CERVICAL DYSPLASIA MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Diagnostic Centers
  • 6.4 Ambulatory Surgical Centers
  • 6.5 Others

7 GLOBAL CERVICAL DYSPLASIA MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East

8 GLOBAL CERVICAL DYSPLASIA MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 QIAGEN
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 F. Hoffmann La-Roche Ltd.
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Quest Diagnostics
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Becton, Dickinson and company
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Abbott Healthcare Pvt. Ltd
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 OncoHealth Corporation, Inc.
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Hologic, Inc.
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments

10 Appendix

  • 10.1 Related Research